{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:39:17Z","timestamp":1789155557336,"version":"build-2803163510"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.mcp.2022.101871","type":"journal-article","created":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T19:28:42Z","timestamp":1666553322000},"page":"101871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer"],"prefix":"10.1016","volume":"66","author":[{"given":"Abig\u00e9l","family":"Balla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong","family":"Bhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-3602","authenticated-orcid":false,"given":"Orsolya","family":"Bir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcp.2022.101871_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.mcp.2022.101871_bib2","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21228855","article-title":"LncRNAs in ovarian cancer progression, metastasis, and main pathways: ceRNA and alternative mechanisms","volume":"21","author":"Braga","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2022.101871_bib4","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.7150\/thno.34692","article-title":"Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression","volume":"9","author":"Chang","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.mcp.2022.101871_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fcell.2019.00182","article-title":"Epigenetic biomarkers in the management of ovarian cancer: current prospectives","volume":"7","author":"Singh","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.mcp.2022.101871_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1042\/BST20180286","article-title":"Detecting ovarian cancer using extracellular vesicles: progress and possibilities","volume":"47","author":"Carollo","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.mcp.2022.101871_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110433","article-title":"Cell origins of high-grade serous ovarian cancer","volume":"10","author":"Kim","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2022.101871_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-64794-8","article-title":"Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma histotypes","volume":"10","author":"Engqvist","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mcp.2022.101871_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semcancer.2021.08.005","article-title":"Platinum-resistant ovarian cancer: from drug resistance mechanisms to liquid biopsy-based biomarkers for disease management","volume":"77","author":"Khan","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.mcp.2022.101871_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11040697","article-title":"What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health organization classification of female genital tumors","volume":"11","author":"de Leo","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.mcp.2022.101871_bib11","first-page":"1","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.mcp.2022.101871_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch."},{"key":"10.1016\/j.mcp.2022.101871_bib13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","article-title":"Synthetic lethality--a new direction in cancer-drug development","volume":"361","author":"Iglehart","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mcp.2022.101871_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/carcin\/bgab043","article-title":"Joint IARC\/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research","volume":"42","author":"Virani","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mcp.2022.101871_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413650","article-title":"Role of circulating biomarkers in platinum-resistant ovarian cancer","volume":"22","author":"Sassu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2022.101871_bib16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.mcp.2022.101871_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102386","article-title":"Liquid biopsy in the clinical management of high-grade serous epithelial ovarian cancer\u2014current use and future opportunities","volume":"13","author":"Paracchini","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2022.101871_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.mcp.2022.101871_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.mcp.2022.101871_bib20","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.7150\/jca.57880","article-title":"WFDC protein: a promising diagnosis biomarker of ovarian cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.mcp.2022.101871_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/9339325","article-title":"A clinical diagnostic value analysis of serum CA125, CA199, and HE4 in women with early ovarian cancer: systematic review and meta-analysis","volume":"2022","author":"Qing","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"10.1016\/j.mcp.2022.101871_bib22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.chest.2016.04.006","article-title":"Human epididymis protein 4: a novel serum inflammatory biomarker in cystic fibrosis","volume":"150","author":"Nagy","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.mcp.2022.101871_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1258\/acb.2011.011258","article-title":"Elevated human epididymis protein 4 concentrations in chronic kidney disease","volume":"49","author":"Nagy","year":"2012","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.mcp.2022.101871_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/br.2016.682","article-title":"The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer","volume":"5","author":"Wei","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.mcp.2022.101871_bib25","first-page":"14141","article-title":"Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model","volume":"13","author":"Wang","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.mcp.2022.101871_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.currproblcancer.2018.06.001","article-title":"Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis","volume":"43","author":"Zhang","year":"2019","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.mcp.2022.101871_bib27","article-title":"Extracellular vesicle-based liquid biopsy holds great promise for the management of ovarian cancer","volume":"1874","author":"Zheng","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.mcp.2022.101871_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000499337","article-title":"Liquid biopsy: general concepts","volume":"63","author":"Poulet","year":"2019","journal-title":"Acta Cytol."},{"key":"10.1016\/j.mcp.2022.101871_bib29","doi-asserted-by":"crossref","first-page":"S1645","DOI":"10.21037\/jtd.2018.04.68","article-title":"Latest development of liquid biopsy","volume":"10","author":"Cheung","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.mcp.2022.101871_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080906","article-title":"Clinical utility of liquid biopsy-based actionable mutations detected via ddPCR","volume":"9","author":"Palac\u00edn\u2010aliana","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.mcp.2022.101871_bib31","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000478018","article-title":"Liquid biopsy: current status and future perspectives","volume":"40","author":"Mader","year":"2017","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.mcp.2022.101871_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100060","article-title":"How to use liquid biopsies to treat patients with cancer","volume":"6","author":"de Mattos-Arruda","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.mcp.2022.101871_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cca.2020.06.047","article-title":"Liquid biopsy in ovarian cancer","volume":"510","author":"Bhardwaj","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.mcp.2022.101871_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10040249","article-title":"Circulating tumor cells enumerated by a centrifugal microfluidic device as a predictive marker for monitoring ovarian cancer treatment: a pilot study","volume":"10","author":"Kim","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.mcp.2022.101871_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-017-0369-5","article-title":"Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer","volume":"10","author":"Cheng","year":"2017","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.mcp.2022.101871_bib36","first-page":"4111","article-title":"Current methodologies to detect circulating tumor cells: a focus on ovarian cancer","volume":"11","author":"Lemma","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.mcp.2022.101871_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133276","article-title":"Functional genomic analysis of breast cancer metastasis: implications for diagnosis and therapy","volume":"13","author":"Yu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2022.101871_bib38","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1038\/s41467-022-31009-9","article-title":"High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells","volume":"13","author":"Boya","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcp.2022.101871_bib39","first-page":"1","article-title":"Novel approaches in cancer management with circulating tumor cell clusters","volume":"4","author":"Rostami","year":"2019","journal-title":"J. Sci.: Advanced Materials and Devices"},{"key":"10.1016\/j.mcp.2022.101871_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-016-0875-0","article-title":"CTC clusters in cancer progression and metastasis","volume":"34","author":"Fabisiewicz","year":"2017","journal-title":"Med. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2019.10.014","article-title":"Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: ready for prime time?","volume":"468","author":"Asante","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mcp.2022.101871_bib42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2017.02.042","article-title":"Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer","volume":"145","author":"Lee","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072653","article-title":"Circulating tumor cell clusters: united we stand divided we fall","volume":"21","author":"Amintas","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2022.101871_bib44","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0735-4","article-title":"Technologies for circulating tumor cell separation from whole blood","volume":"12","author":"Bank\u00f3","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib45","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.7150\/thno.44693","article-title":"A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC","volume":"10","author":"Lim","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.mcp.2022.101871_bib46","doi-asserted-by":"crossref","first-page":"11349","DOI":"10.1021\/ac5035049","article-title":"All-in-one centrifugal microfluidic device for size-selective circulating tumor cell isolation with high purity","volume":"86","author":"Lee","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.mcp.2022.101871_bib47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tjog.2021.11.008","article-title":"Circulating tumor cells as a \u201creal-time liquid biopsy\u201d: recent advances and the application in ovarian cancer","volume":"61","author":"Jou","year":"2022","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"10.1016\/j.mcp.2022.101871_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10040249","article-title":"Circulating tumor cells enumerated by a centrifugal microfluidic device as a predictive marker for monitoring ovarian cancer treatment: a pilot study","volume":"10","author":"Kim","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.mcp.2022.101871_bib49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10549-008-0290-0","article-title":"Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR","volume":"118","author":"Sieuwerts","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.mcp.2022.101871_bib50","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-20-841","article-title":"Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients","volume":"9","author":"Cohen","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.mcp.2022.101871_bib51","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s11684-017-0526-7","article-title":"Application of liquid biopsy in precision medicine: opportunities and challenges","volume":"11","author":"Wang","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.mcp.2022.101871_bib52","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1159\/000492521","article-title":"Analysis of circulating tumor cells in ovarian cancer and their clinical value as a biomarker","volume":"48","author":"Zhang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.mcp.2022.101871_bib53","doi-asserted-by":"crossref","first-page":"7522","DOI":"10.18632\/oncotarget.23943","article-title":"Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer","volume":"9","author":"Guo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcp.2022.101871_bib54","first-page":"3363","article-title":"The added value of circulating tumor cells examination in ovarian cancer staging","volume":"5","author":"Kolostova","year":"2015","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.mcp.2022.101871_bib55","first-page":"973","article-title":"Molecular characterization of circulating tumor cells in ovarian cancer","volume":"6","author":"Kolostova","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.mcp.2022.101871_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2020.573010","article-title":"Non-invasive technology advances in cancer\u2014a review of the advances in the liquid biopsy for endometrial and ovarian cancers","volume":"2","author":"Openshaw","year":"2020","journal-title":"Front Digit Health"},{"key":"10.1016\/j.mcp.2022.101871_bib57","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","article-title":"Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer","volume":"122","author":"Poveda","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2012.09.021","article-title":"Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortium","volume":"128","author":"Obermayr","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib59","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1373\/clinchem.2014.224808","article-title":"ERCC1-Positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance","volume":"60","author":"Kuhlmann","year":"2014","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mcp.2022.101871_bib60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000494411","article-title":"Liquid biopsy for the management of patients with colorectal cancer","volume":"99","author":"Yamada","year":"2019","journal-title":"Digestion"},{"key":"10.1016\/j.mcp.2022.101871_bib61","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.22468","article-title":"Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium","volume":"8","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcp.2022.101871_bib62","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.mcp.2022.101871_bib63","doi-asserted-by":"crossref","first-page":"868","DOI":"10.5306\/wjco.v11.i11.868","article-title":"Liquid biopsy in ovarian cancer: catching the silent killer before it strikes","volume":"11","author":"Feeney","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib64","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/1878-0261.12777","article-title":"DNA in extracellular vesicles: biological and clinical aspects","volume":"15","author":"Elzanowska","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.mcp.2022.101871_bib65","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2217\/bmm-2021-0968","article-title":"Cell-free DNA as a solid-organ transplant biomarker: technologies and approaches","volume":"16","author":"Edwards","year":"2022","journal-title":"Biomarkers Med."},{"key":"10.1016\/j.mcp.2022.101871_bib66","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/10408363.2017.1299683","article-title":"Using circulating cell-free DNA to monitor personalized cancer therapy","volume":"54","author":"Oellerich","year":"2017","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"10.1016\/j.mcp.2022.101871_bib67","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ebiom.2019.10.008","article-title":"Day-to-day and within-day biological variation of cell-free DNA","volume":"49","author":"Madsen","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.mcp.2022.101871_bib68","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4939-8973-7_2","article-title":"Cell-free DNA: an overview of sample types and isolation procedures","volume":"1909","author":"Martignano","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.mcp.2022.101871_bib69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/gcc.22517","article-title":"A field guide for cancer diagnostics using cell-free DNA: from principles to practice and clinical applications","volume":"57","author":"Volckmar","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.mcp.2022.101871_bib70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jmoldx.2016.09.009","article-title":"A comparison of cell-free DNA isolation kits: isolation and quantification of cell-free DNA in plasma","volume":"19","author":"Sorber","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.mcp.2022.101871_bib71","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9306564","article-title":"Current nucleic acid extraction methods and their implications to point-of-care diagnostics","volume":"2017","author":"Ali","year":"2017","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.mcp.2022.101871_bib72","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s12253-018-0382-z","article-title":"Blood collection and cell-free DNA isolation methods influence the sensitivity of liquid biopsy analysis for colorectal cancer detection","volume":"25","author":"Bart\u00e1k","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.mcp.2022.101871_bib73","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/annonc\/mdz227","article-title":"How liquid biopsies can change clinical practice in oncology","volume":"30","author":"Siravegna","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib74","doi-asserted-by":"crossref","DOI":"10.1186\/s12958-021-00860-8","article-title":"Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer","volume":"19","author":"Yang","year":"2021","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.mcp.2022.101871_bib75","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.3390\/cancers13153840","article-title":"Future screening prospects for ovarian cancer","volume":"13","author":"\u017dilovi\u010d","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2022.101871_bib76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12253-016-0174-2","article-title":"Circadian rhythm of methylated septin 9, cell-free DNA amount and tumor markers in colorectal cancer patients","volume":"23","author":"T\u00f3th","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.mcp.2022.101871_bib77","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-020-00971-6","article-title":"High-throughput approaches for precision medicine in high-grade serous ovarian cancer","volume":"13","author":"Govindarajan","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib78","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1158\/1078-0432.CCR-16-1078","article-title":"Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses","volume":"23","author":"Vanderstichele","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcp.2022.101871_bib79","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e32","article-title":"Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma","volume":"30","author":"Kim","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.mcp.2022.101871_bib80","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026252","article-title":"TP53 mutations in breast and ovarian cancer","volume":"7","author":"Silwal-Pandit","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.mcp.2022.101871_bib81","doi-asserted-by":"crossref","first-page":"R663","DOI":"10.1530\/ERC-18-0019","article-title":"The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer","volume":"25","author":"Alharbi","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.mcp.2022.101871_bib82","article-title":"Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes","author":"Giannopoulou","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.mcp.2022.101871_bib83","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mcp.2022.101871_bib84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/1878-0261.12791","article-title":"Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients","volume":"15","author":"Charo","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.mcp.2022.101871_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.mcp.2022.101871_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215364","article-title":"Liquid biopsy to detect minimal residual disease: methodology and impact","volume":"13","author":"Honor\u00e9","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2022.101871_bib87","first-page":"276","article-title":"Circulating tumor DNA and liquid biopsy in oncology","volume":"1","author":"Cescon","year":"2020","journal-title":"Nat. Can. (Que.)"},{"key":"10.1016\/j.mcp.2022.101871_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/biom10030415","article-title":"TP53 mutations in serum circulating cell-free tumor DNA as longitudinal biomarker for high-grade serous ovarian cancer","volume":"10","author":"Vitale","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.mcp.2022.101871_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"Pereira","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.mcp.2022.101871_bib90","first-page":"2022","article-title":"Mitochondrial dysfunction pathway alterations offer potential biomarkers and therapeutic targets for ovarian cancer","author":"Shen","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.mcp.2022.101871_bib91","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.tranon.2019.05.015","article-title":"Circulating mitochondrial DNA is linked to progression and prognosis of epithelial ovarian cancer","volume":"12","author":"Meng","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.mcp.2022.101871_bib92","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jbiotec.2019.04.015","article-title":"Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer","volume":"298","author":"Keser\u0171","year":"2019","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.mcp.2022.101871_bib93","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/carcin\/bgab033","article-title":"The mitochondrial landscape of ovarian cancer: emerging insights","volume":"42","author":"Shukla","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.mcp.2022.101871_bib94","first-page":"323","article-title":"Methylation and ovarian cancer: can DNA methylation be of diagnostic use?","volume":"10","author":"Hentze","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.mcp.2022.101871_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040838","article-title":"Circulating cell-free DNA methylation profiles in the early detection of ovarian cancer: a scoping review of the literature","volume":"13","author":"Guo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2022.101871_bib96","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3892\/ol.2017.6111","article-title":"Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer","volume":"14","author":"Wang","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.mcp.2022.101871_bib97","first-page":"1","article-title":"Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer","volume":"15","author":"Wu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.mcp.2022.101871_bib98","first-page":"1","article-title":"DNA methylation in ovarian cancer susceptibility","volume":"13","author":"Reid","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mcp.2022.101871_bib99","article-title":"Genomic instability and cancer","volume":"5","author":"Yao","year":"2014","journal-title":"J. Carcinog. Mutagen."},{"key":"10.1016\/j.mcp.2022.101871_bib100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10555-013-9429-5","article-title":"The detection and implication of genome instability in cancer","volume":"32","author":"Pikor","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.mcp.2022.101871_bib101","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-20-3345","article-title":"Genome-wide copy-number alterations in circulating tumor DNA as a novel biomarker for patients with high-grade serous ovarian cancer","volume":"27","author":"Paracchini","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcp.2022.101871_bib102","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.3390\/ijms22094409","article-title":"Mechanisms of high-grade serous carcinogenesis in the fallopian tube and ovary: current hypotheses, etiologic factors, and molecular alterations","volume":"22","author":"Otsuka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcp.2022.101871_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10050279","article-title":"CCNE1 amplification as a predictive biomarker of chemotherapy resistance in epithelial ovarian cancer","volume":"10","author":"Gorski","year":"2020","journal-title":"Diagnostics"},{"key":"10.1016\/j.mcp.2022.101871_bib104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","article-title":"Pathogenesis and heterogeneity of ovarian cancer","volume":"29","author":"Kroeger","year":"2017","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.mcp.2022.101871_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015498","article-title":"Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer","volume":"5","author":"Etemadmoghadam","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.mcp.2022.101871_bib106","doi-asserted-by":"crossref","first-page":"812","DOI":"10.18632\/oncotarget.22549","article-title":"Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells","volume":"9","author":"Obermayr","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcp.2022.101871_bib107","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.molonc.2016.04.002","article-title":"Gene expression profiling of single circulating tumor cells in ovarian cancer - establishment of a multi-marker gene panel","volume":"10","author":"Blassl","year":"2016","journal-title":"Mol Oncol"},{"key":"10.1016\/j.mcp.2022.101871_bib108","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.16179","article-title":"EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcp.2022.101871_bib109","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2015.03.002","article-title":"Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs)","volume":"137","author":"Pearl","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.mcp.2022.101871_bib110","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/IGC.0b013e318216cb91","article-title":"Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy","volume":"21","author":"Aktas","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.mcp.2022.101871_bib111","doi-asserted-by":"crossref","first-page":"15266","DOI":"10.18632\/oncotarget.24555","article-title":"PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma","volume":"9","author":"Morikawa","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcp.2022.101871_bib112","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5468\/ogs.2018.61.3.328","article-title":"Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer","volume":"61","author":"Park","year":"2018","journal-title":"Obstet Gynecol Sci"},{"key":"10.1016\/j.mcp.2022.101871_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mcp.2022.101871_bib114","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/1078-0432.CCR-17-0544","article-title":"Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer","volume":"23","author":"Weigelt","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcp.2022.101871_bib115","doi-asserted-by":"crossref","first-page":"466","DOI":"10.21037\/tlcr.2016.10.02","article-title":"Circulating tumor cells versus circulating tumor DNA in lung cancer\u2014which one will win?","volume":"5","author":"Calabuig-Fari\u00f1as","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.mcp.2022.101871_bib116","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mcp.2022.101871_bib117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1940-6207.CAPR-19-0184","article-title":"Reducing ovarian cancer mortality through early detection: approaches using circulating biomarkers","volume":"13","author":"Trinidad","year":"2020","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.mcp.2022.101871_bib118","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tjog.2021.11.008","article-title":"Circulating tumor cells as a \u201creal-time liquid biopsy\u201d: recent advances and the application in ovarian cancer","volume":"61","author":"Jou","year":"2022","journal-title":"Taiwan. J. Obstet. Gynecol."},{"key":"10.1016\/j.mcp.2022.101871_bib119","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-020-00729-1","article-title":"Prediction of the treatment response in ovarian cancer: a ctDNA approach","volume":"13","author":"Sharbatoghli","year":"2020","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.mcp.2022.101871_bib120","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01588-8","article-title":"Potential clinical utility of liquid biopsies in ovarian cancer","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850822000822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850822000822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:19:04Z","timestamp":1760192344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850822000822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":120,"alternative-id":["S0890850822000822"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2022.101871","relation":{},"ISSN":["0890-8508"],"issn-type":[{"value":"0890-8508","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2022.101871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101871"}}